Raltitrexed在许多恶性肿瘤的治疗中表现出治疗效果和安全性。然而，关于以Raltitrexed为基础的经动脉化学栓塞（TACE）或药物释放珠TACE（DEB-TACE）在肝细胞癌（HCC）治疗中的临床结果的报告很少。我们旨在报道在不能手术或复发性HCC患者中使用DEB-TACE装载有Raltitrexed的初步疗效。从2018年6月至2020年3月，我们的科室招募了29例不能手术或复发性HCC患者，并经过DEB-TACE装载Raltitrexed进行治疗。总生存率和无进展生存率是主要终点。肿瘤反应使用修改后的实体瘤反应评估标准（mRECIST）标准进行调查。共进行了49次DEB-TACE会议，技术成功率为100％。 DEB-TACE后1,3和6个月的总反应率和疾病控制率分别为72.0％和96.0％，57.1％和85.7％，47.6％和66.7％。中位无进展生存期和总生存期分别为25.7和33.9个月。6,24和36个月的总生存率分别为88.4％，66.3％和46.3％。轻微的并发症发生在17名患者（58.6％）中，没有治疗相关的死亡或严重不良事件。治疗相关的最常见并发症是腹痛（41.4％）和ALT / AST上升（27.6％）。建议使用DEB-TACE装载Raltitrexed作为不能手术或复发性HCC患者的安全，可行，有效的姑息治疗方案。 ©2023。作者（们）。

Raltitrexed shows therapeutic effects and safety in many types of malignant tumors. However, reports of the clinical outcomes of raltitrexed-based transarterial chemoembolization (TACE) or drug-eluting beads TACE (DEB-TACE) in the treatment of hepatocellular carcinoma (HCC) are rare. We aim to report the preliminary outcomes of DEB-TACE loaded with raltitrexed in patients with unresectable or recurrent HCC.From June 2018 to March 2020, 29 patients with unresectable or recurrent HCC were recruited from our department and treated by DEB-TACE loaded with raltitrexed. Overall survival and progression-free survival were the primary end points. Tumor response was investigated by using the modified response evaluation criteria in solid tumors (mRECIST) criteria.A total of 49 sessions of DEB-TACE were performed, with a technique success rate of 100%. The overall response rate and disease control rate at 1, 3, and 6 months after DEB-TACE were 72.0% and 96.0%, 57.1% and 85.7%, 47.6% and 66.7% respectively. The median progression-free survival and overall survival was 25.7 and 33.9 months, respectively. The 6-, 24- and 36-month overall survival rates were 88.4%, 66.3% and 46.3%, respectively. Minor complications were observed in 17 patients (58.6%), with no treatment-related mortality or severe adverse events. The most common treatment-related complications were abdominal pain (41.4%) and elevated ALT/AST (27.6%).DEB-TACE loaded with raltitrexed is suggested as a safe, feasible, efficacious palliative regimen in unresectable or recurrent HCC patients.© 2023. The Author(s).